Clinical Trials Directory

Trials / Completed

CompletedNCT02431624

An Assessment of Buprenorphine Transdermal Delivery System (BTDS) Patch Adhesion

A Two Period, Randomised, Open-label, Crossover Study to Assess the Adhesion of Buprenorphine Transdermal Delivery System 40 µg/h Patch and 20 µg/h Patch, in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Mundipharma Research Limited · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess the adhesion of BTDS patch 40 µg/h.

Detailed description

The objective is to show non-inferiority in adhesion of BTDS patch 40 µg/h compared to BTDS patch 20 µg/h. Safety and tolerability of both patches will also be assessed.

Conditions

Interventions

TypeNameDescription
DRUGBTDS

Timeline

Start date
2015-03-01
Primary completion
2015-05-01
Completion
2015-11-01
First posted
2015-05-01
Last updated
2016-02-09

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02431624. Inclusion in this directory is not an endorsement.

An Assessment of Buprenorphine Transdermal Delivery System (BTDS) Patch Adhesion (NCT02431624) · Clinical Trials Directory